News & Events zu Genmab A/S (GMAB)GMABGenmab A/S

Genmab Q3 Darzalex Sales Reach $4.239M

Genmab announced that worldwide net trade sales of Darzalex - daratumumab -, including sales of the subcutaneous product sold under the tradename Darzalex Faspro in the U.S., as reported by Johnson & Johnson (JNJ), were $4.239M in Q3. Net trade sales were $2.528M in the U.S. and $1.711M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.

Genmab and AbbVie Announce Positive Results from EPCORE DLBCL-2 Trial

Genmab A/S (GMAB) and AbbVie (ABBV) announced "positive" topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, or R-CHOP, compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma with an International Prognostic Index score of 2 to 5. The trial demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in DLBCL patients with an IPI score of 2 to 5. The risk of disease progression or death was reduced by 51%. The safety profile of epcoritamab when administered in combination with standard of care R-CHOP was generally well tolerated and consistent with the previously reported safety profiles of the individual agents. "These topline results of epcoritamab in combination with R-CHOP mark the first Phase 3 study to demonstrate a statistically significant improvement in progression-free survival in patients with newly diagnosed DLBCL treated with a bispecific antibody combination and have the potential to reshape the frontline treatment landscape," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "While treatment advances have improved outcomes for patients with diffuse large B-cell lymphoma, options for newly diagnosed patients remain limited, reinforcing the need for additional therapies that can treat as many patients as possible in the frontline setting."

Genmab RAINFOL-01 Trial Shows Rina-S Achieves 45.9% Efficacy in Ovarian Cancer

Genmab announced results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan demonstrated that among 109 treated patients with platinum-resistant ovarian cancer, PROC, Rina-S achieved a confirmed objective response rate, ORR, of 45.9%, including five complete responses, CRs, and a median duration of response, mDOR, of 12.1 months, with 51% of responders remaining in response at one year. The findings were presented today in a Late-Breaking Oral Session at the International Gynecologic Cancer Society, IGCS, Congress 2026, held in Montreal, Canada.